HRMY | Harmony biosciences holdings inc - Stock Value & PE Ratio Analysis

3

24

15

Good Growth

AI analysis rates HRMY with a higher value score of 4.
It is mainly due to stable revenue growth, along with stable operating cash flow.
Over the past 3 months, HRMY has maintained a consecutive value rating of 4.0, higher than the rating of 2.0 over the past 3 years, indicating noticeable improvement in enterprise value.
Compared to all stocks in the Health Care sector, HRMY has a higher value rating.

HRMY Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/02/28 (Weekly Update)

HRMY Financial Forecast

Unit : USD

Update to 2025/5/13 (Quarterly Update)

HRMY Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	0.85	88.9%	14.9%	201.27M	19.5%	9.9%	24.8%
2024Q2	0.79	5.3%	17.9%	186.04M	16.1%	-6.3%	6.7%
2024Q1	0.2	-64.3%	-433.3%	172.81M	28.8%	-0.2%	24.8%
2023Q4	0.67	39.6%	11.7%	154.62M	29.8%	0%	15.8%
2023Q3	0.45	-43%	-6.3%	168.41M	31.3%	-0.7%	24%

Update to 2025/5/14 (Quarterly Update)

HRMY Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

HRMY Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of HRMY from 2020/08 till Now

46.01%
Cumulative Return: 8.40%
Annual Return: 25.83%
Volatility: 0.33
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from August, 2020 to May, 2025. (Total Trades: 1)